CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Medicus Sciences Acquisition Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Medicus Sciences Acquisition Corp
152 West 57Th Street, Floor 20
Phone: (212) 259-8400p:212 259-8400 NEW YORK, NY  10019  United States
This company ceased filing statements with the SEC on 2/27/2023.
On 2/13/2023, Medicus Sciences Acquisition Corp. announced that due to its inability to consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association (the "Charter"), the Board of Directors of the Company has elected to dissolve and liquidate the Company in accordance with the provisions of its Charter. As of the close of business on 2/21/2023, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount. The Company anticipates that the Public Shares will cease trading as of the close of business on 2/17/2023.
This company is no longer actively traded on any major stock exchange.
Business Summary
Medicus Sciences Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and it has not initiated any substantive discussions, directly or indirectly, with any business combination target. The Company is focused on pursuing an initial business combination opportunity in any industry or geographical location. It intends to focus on the medical technology sector. The Company neither engages in any operations nor generates any revenues.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202212/31/2021YesYes---

Industries
SIC Code Description
6726 Unit investment trusts, face-amount certificate offices
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board JacobGottlieb 50 11/1/2020 11/1/2020
Chief Executive Officer, Director Michael B.Castor 51 11/1/2020 11/1/2020
Chief Financial Officer JudahDrillick 45 11/1/2020 11/1/2020
4 additional Officers and Directors records available in full report.

Business Names
Business Name
MSAC
MSACU

General Information
Outstanding Shares: 11,615,000 (As of 11/14/2022)
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, October 24, 2024